Insmed (INSM) Competitors $71.07 +0.04 (+0.06%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$71.00 -0.07 (-0.10%) As of 04/15/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INSM vs. TAK, ALNY, ONC, RPRX, TEVA, ITCI, UTHR, SMMT, GMAB, and BMRNShould you be buying Insmed stock or one of its competitors? The main competitors of Insmed include Takeda Pharmaceutical (TAK), Alnylam Pharmaceuticals (ALNY), Beigene (ONC), Royalty Pharma (RPRX), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), United Therapeutics (UTHR), Summit Therapeutics (SMMT), Genmab A/S (GMAB), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "pharmaceutical preparations" industry. Insmed vs. Takeda Pharmaceutical Alnylam Pharmaceuticals Beigene Royalty Pharma Teva Pharmaceutical Industries Intra-Cellular Therapies United Therapeutics Summit Therapeutics Genmab A/S BioMarin Pharmaceutical Insmed (NASDAQ:INSM) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, community ranking, earnings, dividends, media sentiment, risk and analyst recommendations. Which has more volatility and risk, INSM or TAK? Insmed has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. Does the media prefer INSM or TAK? In the previous week, Insmed had 1 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 8 mentions for Insmed and 7 mentions for Takeda Pharmaceutical. Insmed's average media sentiment score of 1.45 beat Takeda Pharmaceutical's score of 0.48 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 2 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is INSM or TAK more profitable? Takeda Pharmaceutical has a net margin of 4.53% compared to Insmed's net margin of -251.24%. Takeda Pharmaceutical's return on equity of 9.39% beat Insmed's return on equity.Company Net Margins Return on Equity Return on Assets Insmed-251.24% -4,773.73% -54.58% Takeda Pharmaceutical 4.53%9.39%4.53% Which has stronger earnings & valuation, INSM or TAK? Takeda Pharmaceutical has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInsmed$363.71M35.53-$749.57M-$5.59-12.71Takeda Pharmaceutical$4.58T0.01$994.06M$0.4036.36 Do analysts rate INSM or TAK? Insmed presently has a consensus price target of $94.00, suggesting a potential upside of 32.26%. Given Insmed's higher possible upside, equities research analysts clearly believe Insmed is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Insmed 0 Sell rating(s) 0 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 3.00Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in INSM or TAK? 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 3.0% of Insmed shares are owned by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer INSM or TAK? Insmed received 455 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 66.83% of users gave Insmed an outperform vote while only 57.06% of users gave Takeda Pharmaceutical an outperform vote. CompanyUnderperformOutperformInsmedOutperform Votes55666.83% Underperform Votes27633.17% Takeda PharmaceuticalOutperform Votes10157.06% Underperform Votes7642.94% SummaryInsmed beats Takeda Pharmaceutical on 9 of the 17 factors compared between the two stocks. Remove Ads Get Insmed News Delivered to You Automatically Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INSM vs. The Competition Export to ExcelMetricInsmedPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.91B$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-12.716.7921.7317.82Price / Sales35.53225.96379.2094.61Price / CashN/A65.6738.1534.64Price / Book-30.635.866.464.00Net Income-$749.57M$141.86M$3.20B$247.23M7 Day Performance5.21%4.50%2.86%1.45%1 Month Performance-7.16%-12.65%-8.55%-6.24%1 Year Performance171.78%-11.06%10.47%0.60% Insmed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INSMInsmed4.1119 of 5 stars$71.07+0.1%$94.00+32.3%+165.0%$12.91B$363.71M-12.71373Positive NewsTAKTakeda Pharmaceutical2.3698 of 5 stars$14.32-2.8%N/A+10.3%$45.62B$4.58T35.8547,300High Trading VolumeALNYAlnylam Pharmaceuticals4.5644 of 5 stars$235.690.0%$316.25+34.2%+56.4%$30.72B$2.25B-108.822,000ONCBeigene2.3091 of 5 stars$221.86-7.0%$310.40+39.9%N/A$21.89B$3.81B-26.9210,600Gap DownRPRXRoyalty Pharma4.516 of 5 stars$31.01-0.3%$41.60+34.1%+14.9%$17.89B$2.26B21.4080Positive NewsTEVATeva Pharmaceutical Industries3.0335 of 5 stars$13.89+0.7%$23.43+68.6%+2.7%$15.81B$16.54B-9.6236,800Analyst DowngradeOptions VolumePositive NewsITCIIntra-Cellular Therapies3.4828 of 5 stars$131.87flat$106.23-19.4%N/A$14.05B$680.50M-151.57560Analyst ForecastPositive NewsUTHRUnited Therapeutics4.903 of 5 stars$290.55-0.7%$388.25+33.6%+21.2%$13.10B$2.88B12.81980Insider TradePositive NewsSMMTSummit Therapeutics2.6134 of 5 stars$17.14-1.2%$35.40+106.5%+573.6%$12.70B$700,000.00-61.50110News CoverageGMABGenmab A/S4.2091 of 5 stars$18.14-1.3%$41.33+127.8%-33.9%$12.05B$21.53B10.461,660Short Interest ↓Gap DownBMRNBioMarin Pharmaceutical4.8888 of 5 stars$59.00-2.1%$94.00+59.3%-34.4%$11.29B$2.85B26.893,401Upcoming EarningsPositive News Remove Ads Related Companies and Tools Related Companies Takeda Pharmaceutical Competitors Alnylam Pharmaceuticals Competitors Beigene Competitors Royalty Pharma Competitors Teva Pharmaceutical Industries Competitors Intra-Cellular Therapies Competitors United Therapeutics Competitors Summit Therapeutics Competitors Genmab A/S Competitors BioMarin Pharmaceutical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INSM) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Insmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INSM Stock Free INSM Stock Alerts